John F. Pottier has been appointed senior director of business development in CEDRA’s Generics unit. He has more than 17 years within the sales and marketing sector of the CRO market with extensive experience in building accounts within the pharmaceutical, generic and biotech industries.

“We are thrilled to have John join us,” said CEDRA chief executive officer Anthony G. Busa, Jr. “His experience with generic drug development programs, teaming up with our expertise in study design and regulatory knowledge, will continue to ensure smooth, efficient bioequivalence studies for our clients. John’s addition will benefit CEDRA in a number of ways and help to ignite the expansion of our generics division.”

Prior to joining CEDRA, Mr. Pottier held positions with Novum Pharmaceutical Research Services and PRACS Institute, Ltd./Cetero Research, all of which were related to business development and enhancing sales and marketing strategies.